A team led by Heng Xue, Xinfeng Li, Guibo Rao, and Hang Yang, working with colleagues including Krystyna Dąbrowska of the Polish Academy of Sciences, focused on AbP20, a podovirus that infects Acinetobacter baumannii, a pathogen notorious for its resistance to last-resort antibiotics. Using a mouse infection model, the researchers asked a deceptively simple question: when the body produces antibodies against a therapeutic phage, which of those antibodies actually matter for treatment outcome? The answer, they found, is far from uniform across the viral particle.

The experimental design began with repeated intraperitoneal administration of AbP20, given once daily for seven consecutive days. This dosing regimen induced a robust phage-specific antibody response in the animals, and those antibodies measurably impaired phage therapy. Rather than treating the antibody response as a single entity, however, the team dissected it at the level of individual viral structural proteins, using a genome-guided antigen screening strategy to determine which components of the virion provoked the most therapeutically damaging immune reactions.

The screening results pointed decisively to two proteins: the nozzle and the fiber. Antibodies elicited by these two structural components, rather than those directed against the portal, the capsid, or the adaptor proteins, emerged as the dominant drivers of phage therapy failure in the mouse model. This specificity is significant because it suggests that the immunological vulnerability of a therapeutic phage is not distributed evenly across its architecture but concentrated in the machinery the virus uses to recognize and penetrate its bacterial host.

The mechanistic follow-up experiments clarified why these two proteins matter so much. Fiber-specific antibodies were found to block bacterial adsorption, the initial step in which the phage attaches to receptors on the surface of Acinetobacter baumannii. Without attachment, the infection cycle cannot begin. Nozzle-specific antibodies, by contrast, acted at a later stage, blocking genomic injection, the moment when the phage delivers its DNA into the bacterial cell. In other words, the two antibody populations sabotage the phage at two distinct and sequential checkpoints of the infection process, one preventing docking and the other preventing entry.

But neutralization inside the dish was only half of the story. The researchers discovered that both fiber-specific and nozzle-specific antibodies also promoted the formation of large phage aggregates in circulation. These antibody-mediated aggregates potentiated phagocytosis by macrophages, the scavenger cells of the immune system, and notably this enhancement occurred through an Fc receptor-independent pathway. That detail is mechanistically important: it implies that the immune clearance of antibody-coated phages does not rely on the classical Fc-mediated uptake route, pointing instead to an alternative mechanism by which macrophages recognize and engulf aggregated viral particles.

The dual action of these antibodies, blocking infection on one hand and accelerating immune clearance on the other, constitutes a synergistic assault on therapeutic efficacy. A phage that cannot attach to or inject into its target bacterium is already crippled, and the same antibodies simultaneously shorten the window of time the phage survives in the body by hastening its removal. The study’s authors describe this as a dual synergistic mechanism through which nozzle- and fiber-elicited neutralizing antibodies impair phage therapy, a framing that captures how the two effects compound rather than merely add together.

To probe whether escaping neutralization could rescue treatment, the team turned to an evolved AbP20 variant with improved neutralization escape capacity. The results were instructive but sobering. This variant exhibited antibody-accelerated phagocytosis and host immune clearance comparable to the parental phage, meaning that evolving away from antibody recognition did not spare it from the clearance arm of the immune response. Nevertheless, the variant partially rescued the therapeutic failure caused by neutralizing antibodies, indicating that the infection-blocking effect is the more decisive contributor to treatment loss, while immune clearance imposes a persistent background cost that escape mutations do not readily evade.

The broader implications for phage therapy development are considerable. Clinical phage programs typically monitor neutralizing antibody titers as a single aggregate measure, but this study suggests that the protein specificity of the antibody response is what ultimately shapes therapeutic outcomes. If antibodies against the portal, capsid, or adaptor proteins are comparatively benign while fiber- and nozzle-directed antibodies are the dominant saboteurs, then rational phage engineering, careful phage selection, or dosing strategies that minimize exposure of the receptor-binding apparatus to the immune system could meaningfully extend the viability of phage treatments in patients who mount strong antibody responses.

For a field racing to keep pace with antimicrobial resistance, the findings offer both a warning and a roadmap. The warning is that repeated phage dosing, a common feature of current treatment protocols, can provoke antibody responses that quietly dismantle therapeutic efficacy through mechanisms that standard efficacy testing may not capture. The roadmap lies in the molecular detail: by identifying the nozzle and fiber proteins as the principal immunological weak points of AbP20, the study provides a concrete framework for predicting which phages are most likely to fail under immune pressure and for designing next-generation therapeutics that either evade these antibodies or tolerate their presence well enough to complete the job.

Subject of Research: Antibody specificity in phage therapy failure against Acinetobacter baumannii

Article Title: Antibodies targeting phage fiber and nozzle proteins impair Acinetobacter baumannii phage therapy by blocking infection and promoting immune clearance

Article References: Xue, H., Li, X., Rao, G., Hu, F., Zhong, M., Miernikiewicz, P., Qiu, R., Cao, S., Dąbrowska, K., & Yang, H. (2026). Antibodies targeting phage fiber and nozzle proteins impair Acinetobacter baumannii phage therapy by blocking infection and promoting immune clearance. PLOS Biology, 24(9), e3004009. https://doi.org/10.1371/journal.pbio.3004009

Image Credits: AI Generated

DOI: 10.1371/journal.pbio.3004009

Keywords: phage therapy, Acinetobacter baumannii, antimicrobial resistance, neutralizing antibodies, fiber protein, nozzle protein, macrophage phagocytosis, podovirus, immune clearance, PLOS Biology, phage aggregates, Fc receptor-independent pathway

The clinical problem the study addresses is formidable. K. pneumoniae is wrapped in a thick capsule composed of long-chain polysaccharides that shields the cell from immune recognition and from many antibiotics. The chemical composition of this capsule defines the K type, and more than 70 distinct K types have been described. Hypervirulent and multidrug-resistant lineages of the bacterium have spread globally, and the enzymes that degrade these capsules, known as depolymerases, have emerged as a promising class of anti-infective agents precisely because they are highly specific: a given depolymerase typically attacks only one capsular serotype, sparing the rest of the bacterial community and, importantly, sparing the patient’s own cells and microbiota.

The phage at the center of the study was isolated against the K57-type K. pneumoniae strain 21AA3004 and proved strictly lytic, meaning it kills its host rather than integrating quietly into the bacterial genome. Transmission electron microscopy revealed its particle morphology, and whole-genome sequencing performed on the DNBSEQ-T7 platform showed a double-stranded DNA genome of 40,795 base pairs. Based on this sequence, the authors classified vB_KpnP_JYSS5 as a novel phage within the order Autographivirales, a group of T7-like viruses well known for their compact genomes and efficient lytic cycles. Genomic analysis also flagged open reading frame 11, ORF11, as the likely depolymerase gene, a prediction the team went on to test experimentally.

Growth parameters matter enormously for any phage being considered as a therapeutic, and vB_KpnP_JYSS5 performed well on these standard benchmarks. Using the double-layer agar plate method, the researchers determined that the optimal multiplicity of infection, the ratio of phage particles to bacterial cells, was 0.001, meaning that a single phage could efficiently clear a large bacterial population. One-step growth experiments showed an average burst size of approximately 114 plaque-forming units per infected cell, a measure of how many progeny virions each infected bacterium releases. The phage also displayed reassuring robustness under environmental stress: it retained infectivity across temperatures from 4 degrees Celsius up to 60 degrees Celsius and remained active across a pH range from 5 to 11, conditions that comfortably encompass the physiological environments where treatment would need to work.

Biofilms represent one of the hardest challenges in modern infectious disease medicine. Within these self-produced matrices of polysaccharide, protein, and extracellular DNA, bacteria become dramatically more resistant to antibiotics and to immune attack, and catheters, ventilators, and implants provide ideal surfaces for their formation. The team evaluated the anti-biofilm activity of both the intact phage and the recombinant Dep11 enzyme using three complementary readouts: plate counting to quantify viable bacteria, scanning electron microscopy to visualize structural damage, and confocal laser scanning microscopy to map live and dead cells within the biofilm architecture. Both agents effectively inhibited the formation of new biofilms by the host strain and, critically, could also degrade biofilms that had already established themselves, breaking open a structure that conventional antibiotics often penetrate poorly.

Dep11, the protein product of ORF11, emerged as the study’s most versatile candidate. When expressed recombinantly and applied to K57-type bacteria, the enzyme visibly degraded the capsular polysaccharide, confirming its predicted function. Loss of the capsule has consequences that ripple through every layer of host defense. The researchers showed that Dep11 treatment suppressed biofilm formation and eliminated mature biofilms, but the enzyme’s benefits extended further into synergistic antibacterial therapy. By removing the capsule, Dep11 made the bacteria more vulnerable to two clinically important antibiotics, polymyxin B and gentamicin, potentiating their activity against the target strain. This kind of enzyme-antibiotic synergy is particularly attractive in an era when dose escalation of toxic drugs such as polymyxins carries significant risks for patients.

The immunological experiments added another dimension to the therapeutic case. Macrophages, the tissue-resident scavenger cells of the innate immune system, struggle to engulf encapsulated bacteria because the slippery polysaccharide coat prevents firm attachment and internalization. When the team treated K. pneumoniae with Dep11 and then exposed the bacteria to macrophages, phagocytic uptake increased measurably, as assessed by plate counting, enzyme-linked immunosorbent assay, and flow cytometry. In other words, the enzyme does not kill bacteria directly in the way an antibiotic does; instead, it disarms them, converting an invisible, ungraspable pathogen into an accessible target for the host’s own immune machinery. This mechanism of action also suggests a lower selective pressure for the emergence of widespread resistance compared with conventional bactericidal drugs, although capsular variation among circulating strains remains a constraint that any depolymerase-based therapy must confront.

The most striking results came from the animal model. The researchers established systemic infection by injecting K. pneumoniae intraperitoneally into mice and then treating the animals with Dep11. A 50-microgram dose of the enzyme raised the survival rate of infected mice to 70 percent, a substantial improvement over untreated controls. Beyond survival, the treatment dampened the inflammatory storm that accompanies severe Klebsiella sepsis: concentrations of four pro-inflammatory cytokines, interleukin-1 beta, interleukin-6, tumor necrosis factor alpha, and interferon gamma, were all significantly lowered in the lung tissue of treated animals. This dual effect, improved survival together with reduced inflammatory signaling, indicates that capsule removal not only facilitates bacterial clearance but may also blunt the tissue damage driven by an overexuberant immune response.

The study was approved by the Ethics Committee of the First Affiliated Hospital of Hebei North University and by the institution’s Laboratory Animal Ethics Committee, and the authors report no competing interests. The work was funded by the Zhangjiakou Basic Research and Talent Cultivation Program and by cultivation research projects at Hebei North University. As with any preclinical phage or enzyme study, the path from mouse model to clinical use involves hurdles that the current experiments do not address, including dosing in humans, pharmacokinetics, immunogenicity of a repeatedly administered bacterial enzyme, and the practical need to identify the capsular type of a patient’s infecting strain before a serotype-specific agent like Dep11 can be deployed.

Nevertheless, the findings sharpen a strategy that is gaining momentum in the field of anti-infective research. Rather than relying on whole phage particles alone, which face regulatory complexity and the possibility of bacterial resistance through receptor modification, many groups are now isolating the depolymerase enzymes that phages use to pierce the capsule at the start of infection. These enzymes act as precision tools: they are chemically defined, can be produced recombinantly at scale, do not replicate, and can be combined with antibiotics or with the immune system. The characterization of vB_KpnP_JYSS5 and Dep11 adds a validated reagent for the K57 serotype to this growing toolbox and provides a template for how phage genomics, protein biochemistry, microscopy, and animal modeling can be woven together to move a candidate enzyme from sequence to therapeutic proof of concept.

Subject of Research: Characterization of the lytic phage vB_KpnP_JYSS5 and its depolymerase Dep11 targeting the K57 capsular type of Klebsiella pneumoniae for anti-biofilm and anti-infection therapy

Article Title: The virulent phage vB_KpnP_JYSS5 and its depolymerase Dep11 targeting K57 Klebsiella pneumoniae: characterization and therapeutic potential against biofilm and systemic infection

Article References: The virulent phage vB_KpnP_JYSS5 and its depolymerase Dep11 targeting K57 Klebsiella pneumoniae: characterization and therapeutic potential against biofilm and systemic infection. (n.d.). https://doi.org/10.1186/s12985-026-03288-x

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03288-x

Keywords: Klebsiella pneumoniae, bacteriophage, depolymerase, Dep11, K57 capsular type, biofilm, capsular polysaccharide, phage therapy, macrophage phagocytosis, antibiotic synergy, systemic infection, Autographivirales